Immunization

Ocugen, Inc. has submitted a request to the FDA for emergency use authorization (EUA) of their COVID-19 vaccine candidate for use in children aged 2 to 18 years.

To date, the best recombinant zoster vaccine (Shingrix) is the best protection against shingles and its complications.

The FDA has notified Moderna that it will need additional time to complete its evaluation of Moderna’s EUA request for the use of the company’s COVID-19 vaccine at the 100-µg dose level in adolescents between 12 and 17 years.

The next step in the approval process is the formal acceptance of the recommendation by CDC Director Rochelle P. Walensky, MD, MPH.

The US Food and Drug Administration (FDA) committee voted on whether the emergency use authorization should be extended to children aged 5 to 11 years.

"The spread of misinformation and mistrust in doctors and science is contributing to staggeringly low vaccination rates among pregnant people," said the American Colleges of Obstetricians and Gynecologists.

The FDA and CDC have both issued their respective recommendations for the rollout of Pfizer-BioNTech and Moderna COVID-19 vaccine boosters.

Immunization Information Systems provide confidential, population-based, computerized database that records all immunization doses administered by participating providers within a geographic area.

FDA gives OK to shingles vaccine for those at risk

Researchers examined the effects of severe acute respiratory infections on pregnancy and reported some concerning findings.

Study findings reveal decreased risk of HZ infection

Pharmacists can promote vaccinations to at-risk individuals.

Good Neighbor Pharmacy (GNP) has allocated more than 2 million doses of COVID-19 vaccines to more than 1500 independent pharmacies through its partnership with the Federal Retail Pharmacy Program.

Independent pharmacies can turn this opportunity into a revenue strem

Novavax Incorporation announced on Monday that its combined flu and COVID-19 vaccine elicited working antibodies against the viruses in a preclinical study.

The Centers for Disease Control and Prevention released new findings that reveal the safety of COVID-19 vaccination in pregnant women.

Drug Topics® sat down with Dr. Daniel Streetman, PharmD, to discuss patients with compromised immune systems and reported responses to COVID-19 vaccines and others.

The FDA EUA for the COVID-19 vaccine will remain in effect for those 12 to 15 years of age and for the administration of a third dose.

A study published in JAMA Internal Medicine explained that a first dose reaction to COVID-19 vaccination should not deter people from receiving their second dose.

For children who have either experienced a delay in pertussis vaccination or who haven’t received the recommended number of doses, what is their risk of pertussis? A new study provides answers.

Recombinant zoster vaccine (Shingrix; GlaxoSmithKline) is now also indicated for the prevention of shingles in immunocompromised adults 18 years and older.

Pharmacists can work with their patients to address concerns about vaccinations.

"Patient care doesn't stop with COVID-19"

Johnson & Johnson released a statement providing more information on the risks and benefits of its single-shot COVID-19 vaccine.

Pharmacists reflect on their takeaways from the experience and how to move forward.

Administering pediatric immunizations can be a window of opportunity for pharmacists to demonstrate their value.

This article is sponsored by STChealth. 

In part 2 of our interview, Jason Ausili, PharmD, speaks to the challenges of COVID-19 vaccination processes and dives into technology solutions for these workflow barriers.

There was a marked decline in child and adolescent routine vaccine administration during the COVID-19 pandemic between March and September 2020; these vaccination rates have continued to lag behind.

Novavax’s recombinant nanoparticle protein-based COVID-19 vaccine showed an overall efficacy of 90.4% and 100% efficacy against moderate and severe disease.